Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease
| Autor: | Saraf, Santosh L., Hagar, Robert, Idowu, Modupe, Osunkwo, Ifeyinwa, Cruz, Kimberly, Kuypers, Frans A., Brown, R. Clark, Geib, James, Ribadeneira, Maria, Schroeder, Patricia, Wu, Eric, Forsyth, Sanjeev, Kelly, Patrick F., Kalfa, Theodosia A., Telen, Marilyn J. |
|---|---|
| Zdroj: | In Blood Advances 27 August 2024 8(16):4459-4475 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|